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David G. Armstrong, PhD, DPM, MD, and Joseph L. Mills Sr, MD, Tucson, Ariz
Objective: Patients requiring lower extremity revascularization are increasingly complex. Traditional means of evaluating
perfusion before and after revascularization are often limited by the presence of medial calcinosis, open wounds, prior toe
or forefoot amputations, and infection. We evaluated the initial application of indocyanine green angiography (ICGA) to
patients with severe lower extremity ischemia to develop quantitative, reproducible parameters to assess perfusion.
Methods: ICGA uses a charge-coupled device camera, a laser, and intravenous contrast to visually assess skin surface
perfusion. From January 2011 to April 2012, we performed ICGA within 5 days of 31 revascularization procedures in
patients with Rutherford class 5 and 6 ischemia. We also compared ICGA before and after revascularization in a subset of
13 patients. We evaluated multiple, quantitative parameters to assess perfusion.
Results: Twenty-four patients underwent ICGA associated with 31 revascularization procedures (26 endovascular, four
open, one hybrid) for 26 lower limb wounds; 92% were diabetic and 20% were dialysis-dependent. In 50% of these
patients, it was not possible to measure ankle-brachial indexes due to medial calcinosis. Paired analysis of ingress (increase
in pixel strength [PxS]), ingress rate (slope of increase in PxS), curve integral (area under the curve in PxS over time), end
intensity (PxS at end of study), egress (decrease in PxS from maximum), and egress rate (slope of decrease in PxS)
increased signiﬁcantly (P < .05) after revascularization.
Conclusions: ICGA provides rapid visual and quantitative information about regional foot perfusion. We believe this is the
ﬁrst report describing quantiﬁcation of foot perfusion before and after lower extremity revascularization for severe limb
ischemia. Further study is warranted to help deﬁne the utility of this intriguing new technology to assess perfusion,
response to revascularization, and potentially, to predict likelihood of wound healing. (J Vasc Surg 2013;57:1213-8.)Although the deﬁnition remains somewhat imprecise,
critical limb ischemia (CLI) associated with tissue loss is
a major, global medical problem. Estimates of CLI inci-
dence in North America and Europe place the ﬁgure at
500 to 1000 new cases/million people per year.1 This inci-
dence is likely to increase due to the aging of the popula-
tion and the epidemic of diabetes. Ischemia severe
enough to cause rest pain and tissue loss is associated
with a 20% annual mortality rate,2 which is higher than
many forms of cancer.3-5 Wound healing and amputation
prevention are not likely in many such patients without
revascularization. Although existing systems such as the
Rutherford6 or Fontaine7 classiﬁcations provide clinical
descriptors to stratify the severity of limb ischemia, no
current system adequately classiﬁes the spectrum of
wounds, infection, and perfusion deﬁcits present in thisthe Department of Surgery, Division of Vascular Surgery, Southern
rizona Limb Salvage Alliance (SALSA), University of Arizona.
or conﬂict of interest: none.
ented at the Rapid Session of the 2012 Vascular Annual Meeting of the
ciety of Vascular Surgery, National Harbor, Md, June 7-9, 2012.
rint requests: Joseph L. Mills Sr, MD, University of Arizona, Depart-
ent of Surgery, Division of Vascular and Endovascular Surgery, 1501
Campbell Ave, PO Box 245072, Tucson, AZ 85724-5072 (e-mail:
ills@u.arizona.edu).
editors and reviewers of this article have no relevant ﬁnancial relationships
disclose per the JVS policy that requires reviewers to decline review of any
anuscript for which they may have a conﬂict of interest.
-5214/$36.00
yright  2013 by the Society for Vascular Surgery.
://dx.doi.org/10.1016/j.jvs.2012.10.113complex group of patients to properly direct their manage-
ment. For more than a generation, attempts have been
made to develop objective criteria for the deﬁnition of
CLI8,9 as well as quantiﬁable threshold measurements of
perfusion that would be sufﬁcient to ensure wound healing.
There are several deﬁnitions of CLI using criteria such
as tissue loss, ankle-brachial index (ABI), absolute systolic
ankle pressure or toe systolic pressure, and transcutaneous
oximetry. However, the applicability of these measure-
ments to the complete spectrum of patients with lower
extremity ischemia, particularly those with diabetes, has
not been established. Target levels of perfusion predictive
of healing in patients with and without diabetes also remain
ill deﬁned. Current clinical methods of measuring limb
perfusion and hemodynamics are all too often limited by
a variety of issues, including the presence of open or
infected wounds, or both, previous toe or forefoot infec-
tions, and medial calcinosis causing false elevation of
systolic pressures. Furthermore, these measurements are
frequently unable to demonstrate regional perfusion
changes, limiting their applicability to many patients with
compartmental foot ischemia such as patients with heel
ulcers or signiﬁcant microvascular disease.
Transcutaneous tissue oxygenation and thermal map-
ping have been used to help augment the information
provided by standard Doppler arterial waveform and pres-
sure measurements.10 These techniques potentially provide
regional perfusion information lacking with ankle or toe
waveforms and pressures and have been used to predict
amputation levels.11 However, they have also shown1213
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all clinical utility. A recent meta-analysis suggests the need
for further study to establish solid guidelines for the predic-
tion of wound healing as well as to establish whether such
studies provide additional, clinically meaningful informa-
tion beyond that gained from more simply obtained clinical
data.12 There currently is no widely accepted standard for
measurement of tissue perfusion in vascular laboratories
or wound care centers.
Indocyanine green (ICG) is an inert, water soluble,
nonradioactive and nontoxic contrast agent, which has
been approved by the U.S. Food and Drug Administration
since 1959. After intravenous injection, ICG is distributed
throughout the intravascular space, where it is rapidly
bound to plasma proteins. By using a laser light source
and a charge-coupled camera, ICG can be made to ﬂuo-
resce with intensity proportional to the perfusion to a given
area. ICG angiography (ICGA) has the potential to
provide regional perfusion information lacking in standard
Doppler-derived arterial pressure and waveform measure-
ments. This technology has been used for decades in
various clinical areas, and its application is expanding to
include assessing viability of skin ﬂaps, measuring hepatic
function, and the probability of complications after trans-
plantation13 and perfusion of bowel,14 tumors, and
muscles. One previous publication demonstrated its use
in the subjective assessment of tissue perfusion in patients
with CLI and tissue loss.15
ICGA provides excellent images of regional perfusion
over time after intravenous administration. To date,
however, there are no established objective criteria for
the application of ICGA in the assessment of tissue and
foot perfusion in patients with peripheral arterial disease
and foot wounds. If objective, quantiﬁable, and reproduc-
ible parameters of perfusion could be derived, it would
immensely aid clinical decision making in determining the
need for and success of revascularization procedures and
in directing wound management and closure. ICGA may
also be less hampered by the traditional limitations of
commonly used Doppler-derived pressure measurements
and the problems with reproducibility associated with oxi-
metry. To this end, we evaluated our initial application of
ICGA and developed a method to provide quantitative,
reproducible endpoints of perfusion.
METHODS
We abstracted data from patients at a single, academic
medical center from January 2011 to April 2012 who
underwent ICGA as part of an evaluation for Rutherford
class 5 or 6 ischemia. This study was approved by the
University of Arizona’s Human Subjects Protection
Committee. The major study inclusion criterion was the
performance of ICGA of the wound site within 5 days of
an attempted revascularization procedure. When available,
pre- and post-intervention ICGA studies were compared in
a subset analysis. Patients were assessed for the presence of
major atherosclerotic risk factors and other comorbidities.
Patients with previous adverse reactions to iodinatedcontrast agents were considered to have an absolute
contraindication to ICG administration and did not
undergo ICGA. Clinical electronic medical notes were
reviewed to assess progression of the wound, and healing
was deﬁned as complete healing/resolution of the wound
either by secondary intention or 100% take of skin graft
for wound closure. Owing to the complexity of many of
the wounds and the relatively short duration of follow-up
compared with average wound healing time in this initial
pilot project, the potential use of ICGA to predict wound
healing was not possible.
ICGA uses a charge-coupled device camera, a laser
source, and intravenous contrast to assess skin surface
perfusion. ICG is rapidly bound to plasma albumin upon
intravenous administration and is exclusively excreted
through the biliary system in an unconjugated form,
without enterohepatic circulation, and a half-life in blood
of 2.5 to 3 minutes. ICG can be safely administered
multiple times to the same person and has an exceedingly
low incidence of adverse reactions (1/60,000 doses).15,16
Excitation of the molecule with the 40 mW/cm laser at
806 nm causes the molecule to ﬂuoresce in a predictable
fashion at 830 nm, a process that can then be detected
by the charge-coupled device camera to demonstrate
greater intensity at areas of increased perfusion. This study
used the SPY system (Novadaq, Bonita Springs, Fla).
The areas of ﬂuorescence intensity can be viewed in
grayscale with whiter indicating higher intensity, or in
a heat-map mode where red indicates high intensity and
blue indicates low intensity. The captured images are dis-
played on a monitor, and the device processes multiple
calculations to provide numerical values derived from the
relation between pixel strength over time.
In evaluating the ICGA studies, multiple objective data
points were obtained and analyzed for potential application
to objectively and reproducibly assess perfusion and, in the
future, to potentially predict healing. These data points
included the starting ﬂuorescent intensity upon initiation
of the ICGA study (starting intensity), the magnitude of
intensity increase from baseline to peak intensity (ingress),
the rate of intensity increase from baseline to peak intensity
over time (ingress rate), the area under the curve of inten-
sity over time (curve integral), the intensity at the end of
the study (end intensity), the magnitude of intensity
decrease from peak intensity to the end of the study
(egress), and the rate of intensity decrease from peak inten-
sity to the end of the study (egress rate). These indicators
can be seen graphically in Fig 1.
RESULTS
During the 16-month study period, 24 patients (83%
men) underwent 31 revascularization procedures for Ruth-
erford class 5 (69%) or 6 (31%) ischemia. The usual comor-
bidities and risk factors were present. Patients were a mean
age of 64.5 6 11.2 years; 16.7% were active smokers,
16.7% were former smokers, and the remaining 66.7%
denied a smoking history. Diabetes (92%), hypertension
(92%), and hyperlipidemia (83%) were almost universally
Table I. Indocyanine green angiography (ICGA) protocol
d Clear the patient of contraindications.
d Position the camera head perpendicular to the area of interest,
adjusting bed height if necessary.
d Reconstitute 12.5 mg indocyanine green in 5 mL normal saline.
d Remove any dressings and extinguish overhead lights.
d Push 5 mL intravenously and immediately ﬂush with normal
saline.
d Start the buffering once the indocyanine green is administered
and start capture when a blush appears on the screen. Capture
the full sequence of 136 seconds without moving the camera
or area of interest. Afterward, capture sequences of any other
tissue that is relevant.
d Return the patient and machines to the original position.Fig 1. Indocyanine green angiography (ICGA) parameter deﬁni-
tions are represented graphically. See text for full deﬁnitions.
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coronary artery disease, 16.7% with chronic obstructive
pulmonary disease, 20.8% with chronic kidney disease
requiring hemodialysis, and two renal transplant recipients,
one of whom had graft failure and required resumption of
hemodialysis. In 50% of the patients, ABIs and toe pres-
sures were unreliable due to medial calcinosis.
Four of the 31 revascularization procedures (12.9%)
were open, 83.9% were endovascular, and one was by
a hybrid approach. Unilateral lesions were treated in 24
patients. Two patients later developed contralateral lower
extremity wounds resulting in 26 limbs studied. Twenty
procedures were performed on the right leg and 11 on
the left, and 51.6% involved occlusion of one or more
involved arteries.
Mean follow-up time after revascularization was 163 6
136 days (range, 13-475 days). In six legs (23%), the
wound healed completely during the follow-up period,
with an average healing time of 181 6 81 days (range,
81-309 days).
Two patients died during the follow-up period, one
from a presumed myocardial infarction #1 week of
below-knee amputation and the other after he chose
hospice treatment because of multiple medical problems,
including end-stage liver disease and chronic ischemic
cardiomyopathy.
Assessment of perfusion was performed using ICGA in
all patients with no adverse reactions. Further analysis was
performed on the subset of vascular interventions with
analyzable ICGA before and after intervention. Early in
the study, not all ICG angiographies were analyzable until
our method of angiography was standardized and repro-
ducible. This was improved by the interim implementation
of a standardized protocol (Table I), with emphasis on not
interrupting the ICGA study to move the foot or the
camera. All studies that then followed this protocol were
analyzable.
Analysis of the 13 patients with ICGA studies before
and after the intervention showed successful revasculariza-
tion that resulted in statistically signiﬁcant improvement in
the ingress, ingress rate, curve integral, end intensity,
egress, and egress rate (Table II). The ICGA parameters
were also compared with traditional measurements ofABI and toe pressures, when available. ABI showed signif-
icant correlation with toe pressures, ingress, ingress rate,
and egress rate (Table III). Toe pressures signiﬁcantly
correlated with ingress rate and a strong tendency with
ingress (P ¼ .051).
DISCUSSION
ICGA provides qualitative information regarding
perfusion in a variety of clinical settings. Its greatest poten-
tial application may lie in further objective study of quanti-
ﬁable data measurements that can be quickly and reliably
derived from the images to determine tissue perfusion,
changes in perfusion after revascularization, and predict
the likelihood of wound healing. This was a pilot study
of nonconsecutive patients with Rutherford 5 and 6
ischemia treated in our unit. We believe it is the ﬁrst
attempt to quantify perfusion by ICGA in such patients
before and after open or endovascular revascularization.
This pilot study was unable to demonstrate levels of
ICGA parameters above which healing can be predicted
or below which nonhealing could be predicted. However,
before a study of sufﬁcient magnitude can be designed,
we ﬁrst have to know where to look. Multiple parameters
could be gleaned from ICGA, but only those that appear
to correlate with increased blood ﬂow after revasculariza-
tion would seem to be good candidates for a wound-
healing study.
Obtaining adequate data in many study patients was
initially challenging. No formal protocol to assess foot
perfusion had ever been described. It was not until we
developed the protocol described in Table I that the infor-
mation obtained became reproducible with reliability.
Many of our initial studies could not be properly analyzed
in a quantitative manner because the limb was often moved
and rotated to look for areas of poor perfusion. Over time,
we were able to develop standardized techniques and
criteria for the use of ICGA in all of our patients presenting
with tissue loss.
The challenge for developing solid criteria for CLI
continues to be a source of debate given that multiple deﬁ-
nitions have been proposed. The lack of solid, standardized
parameters to deﬁne CLI will likely persist due to the
complex interchange of varying wound conditions,
Table II. Indocyanine green angiography (ICGA) parameter values in 13 studies before and after the intervention
Time Start intensity Ingress Ingress rate Curve integral End intensity Egress Egress rate
Before
Mean 8.7 29.7 1.0 34,487.0 36.8 1.2 0.1
SD 11.7 17.2 0.7 29,317.3 26.7 1.4 0.4
After
Mean 12.0 59.2 3.4 71,659.4 54.4 16.7 0.4
SD 17.9 30.1 2.7 61,448.4 34.4 11.4 0.5
P .397 .004 .015 .021 .019 .004 .013
SD, Standard deviation.
Table III. Correlation of ankle-brachial index (ABI ) and
toe pressures with indocyanine green angiography (ICGA)
parameters
Variable No.
R
(Pearson) P Variable No.
R
(Pearson) P
ABI Toe
Toe 16 0.561 .019
Start 21 0.084 .711 Start 16 0.317 .215
Ingress 21 0.450 .036 Ingress 16 0.481 .051
Ingress
rate
21 0.435 .043 Ingress
rate
16 0.636 .006
Curve 21 0.248 .266 Curve 16 0.420 .093
End 21 0.320 .147 End 16 0.443 .075
Egress 21 0.255 .252 Egress 16 0.412 .101
Egress
rate
21 0.503 .017 Egress
rate
16 0.250 .333
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come together to become limb-threatening.17-20 It is inter-
esting to note that the original deﬁnition of CLI excluded
patients with diabetes (or recommended they be separately
considered). The increasing prevalence of diabetes is of
great signiﬁcance when considering treatment options
and outcomes of therapy for patients with diabetes and
a broad spectrum of extremity wounds, ischemia, and
underlying infection. Other methods of evaluating perfu-
sion for assessing the likelihood of healing and response
to revascularization are likely necessary to meet this
challenge.
Current standard techniques of measuring ABIs and
toe pressures have signiﬁcant limitations. In our small
study, 50% of the patients had evidence of medial calcinosis,
making these measurements unreliable. In addition, the
presence of wounds in combination with prior foot-level
amputations frequently prevents adequate measurements.
Furthermore, as previously stated, these studies lack the
ability to provide regional perfusion information. This limi-
tation is frequently of critical importance, such as in patients
with heel ulcers. Fig. 2 shows one example of the power of
regional perfusion information on such a patient. This
patient’s heel ulcer later healed despite an occluded poste-
rior and anterior tibial artery, with perfusion coming solely
from an angioplastied peroneal artery. Although the medial
calcaneal branch of the posterior tibial artery is expected tofeed the angiosome of the plantar heel,21 improvement in
perfusion was evident using ICGA.
ICGA offers multiple advantages as a potential tool in
perfusion evaluation. It can rapidly provide qualitative visual
and quantitative information to the clinician. ICGA is easily
repeatable, with a very low incidence of adverse effects, and
due to its hepatic clearance, can be safely used in patients
with renal insufﬁciency, a common comorbidity in vascular
surgery patients. The camera can also be used to provide
this information on other parts besides the area of concern.
ICGA is not without criticism. Most notable in its limita-
tions are the need for intravenous access for injection and
the added cost of the equipment and the ICG. Further
study is necessary to see if the beneﬁts outweigh the risks.
There are multiple exciting areas of future study we plan
to investigate with ICGA. Further work will help to deter-
mine the reproducibility of the studies and the inherent vari-
ability of the parameters in question as well as other
parameters to be explored. One group has found encour-
aging preliminary data with using the time to maximum
intensity (Tmax) as an indicator in patients with Raynaud
phenomenon.22 Plans are currently underway for gathering
data prospectively for evaluation of ICGA in associationwith
healing as well as indicators for delayed wound closure or
readiness for skin grafting, or both. Our current study was
too small and the follow-up too short to produce reliable
data to predict wound healing.
In contrast to ABI, toe pressures, and transcutaneous
pressure of oxygen, ICGA is not limited by medial calci-
nosis. Nonetheless, the depth of penetration is limited to
5 mm. Eventual hopes may be to see if it becomes a reliable
tool for deﬁning and grading CLI, evaluating compart-
mental or regional ischemia, such as in patients with heel
ulcers or chronic kidney disease. In addition, it would be
interesting to see if future application could help in the
decision-making process of determining which anatomic
lesions to treat in patients with multilevel disease.
CONCLUSIONS
ICGA provides rapid qualitative visual and quantitative
information about regional foot perfusion. Although studies
using this substance have been published for decades, its
application to patients with tissue loss and CLI is still in its
infancy. Lessons learned provide new opportunities for
improved experimentation and application. Our early
Fig 2. Indocyanine green angiography (ICGA) images are shown for a 61-year-old diabetic male with a palpable
dorsalis pedis pulse and a chronic heel ulcer present for 15 months. Angiography revealed a posterior tibial occlusion
that could not be treated. Therefore, angioplasty of the tibioperoneal trunk and peroneal artery tandem stenoses was
performed. He healed completely in 6 weeks. A, An ICGA grayscale image with curve is shown in the patient before
intervention. B, An ICGA grayscale image with curve for the patient after intervention shows a sixfold increase in the
ingress rate and appearance of egress. C, An ICGA heat-map images are shown (C) before intervention and (D) after
intervention.
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warranted in this most clinically practical and intriguing
area.
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